Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | NCOA2 | Q15596 | 3/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 3/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29858085 | 0.78 | POLB (0.50) | POLBHSD17B10SMN1; SMN2NPC1RAB9A | |
| SCHEMBL26917296 | 0.78 | POLB (0.50) | POLBHSD17B10SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9955393 | 0.78 | GAA (0.43) | POLBHSD17B10HPGDNPSR1TDP1 | |
| SCHEMBL21761104 | 0.77 | DAO (0.40) | POLBHSD17B10HPGDNPSR1TDP1 | |
| SCHEMBL16007340 | 0.77 | SCN9A (0.39) | HSD17B10DAOSMN1; SMN2NPC1RAB9A | |
| SCHEMBL20680345 | 0.74 | ALDH1A1 (0.41) | POLBHSD17B10HPGDNPSR1TDP1 | |
| SCHEMBL26130944 | 0.74 | MAOB (0.43) | POLBHSD17B10HPGDNPSR1TDP1 | |
| SCHEMBL31238875 | 0.74 | MAOB (0.43) | POLBHSD17B10HPGDNPSR1TDP1 | |
| SCHEMBL17927636 | 0.73 | HSD17B10 (0.41) | POLBHSD17B10HPGDNPSR1DAO | |
| SCHEMBL29858070 | 0.72 | MEN1 (0.46) | POLBHSD17B10HPGDSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105008367-B | It is used as the pyrrolo-triazine class compound of potassium channel inhibitors | 百时美施贵宝公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-105026399-B | As the pyrrolo-triazine class compound of potassium channel inhibitors | 百时美施贵宝公司 | 2017-06-23 | — | — | CN | disclosed |
| EP-2970294-B1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-28 | — | — | EP | disclosed |
| EP-2970296-B1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2970296-B1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9403834-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403834-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403834-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2970294-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970296-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2014143610-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014143606-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014143606-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014143610-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNJ2, KCNA4 | POLB 3412/4885HSD17B10 2056/4885HPGD 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.